---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008070"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:03:54.261211+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics Q1 net loss $2.8M; cash $32.4M; APR-1051 IND cleared; Phase 1 starts June 2024

## Summary
- Net loss of $2.8M ($0.67 per share) vs $4.4M ($1.34) in prior year; operating loss $3.1M down from $4.6M.
- Cash and equivalents $32.4M as of March 31, 2024, up from $21.6M at Dec 31, 2023; runway into Q3 2025.
- FDA cleared IND for APR-1051 (WEE1 inhibitor) in March 2024; Phase 1 ACESOT-1051 trial expected to start June 2024.
- Phase 1/2a ATRN-119 (ATR inhibitor) trial continues; dose escalation completion expected 4Q 2024; initial efficacy data possible 2H 2024.
- Completed $16M upfront private placement in March 2024 with potential for additional $18M warrants; appointed Nadeem Mirza as CMO effective May 1, 2024.

## SEC filing metadata
- accession: 0001558370-24-008070
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/0001558370-24-008070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/apre-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008070
- JSON: https://secwatch.observer/filing/0001558370-24-008070.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008070.txt

## Key facts
- Earnings Releases
  Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1781983/000155837024008070/0001558370-24-008070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.